The usually conservative group spends big on Dicerna – but others might be interested too.
Company takeovers with promises of more cash down the road ticked up this year, a new Evaluate Vantage analysis finds.
Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.
The addition of Celgene made Bristol’s sales team pharma’s most productive last year on one measure, but the accolade might be short-lived.
The first quarter of 2021 saw fewer deals than any in recent memory.
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.